Gasotransmitters in cancer: From pathophysiology to experimental therapy

Nature Reviews Drug Discovery

Volumn 15, Issue 3, 2016, Pages 185-203

  Szabo, Csaba ^a  

^a University of Texas Medical Branch School of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGUANIDINE; ANTINEOPLASTIC AGENT; CARBON MONOXIDE; CYCLIC AMP; CYCLIC GMP; CYTOCHROME C OXIDASE; ENDOTHELIAL NITRIC OXIDE SYNTHASE; GASOTRANSMITTER; GUANYLATE CYCLASE; HEME OXYGENASE; HYDROGEN SULFIDE; INDUCIBLE NITRIC OXIDE SYNTHASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; N(G) NITROARGININE METHYL ESTER; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; NITRIC OXIDE; OB 24; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE C; PROTOPORPHYRIN TIN; PROTOPORPHYRIN ZINC; STANNSOPORFIN; TISSUE INHIBITOR OF METALLOPROTEINASE 1; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ANTIOXIDANT ACTIVITY; APOPTOSIS; CANCER SURVIVAL; CELL PROTECTION; CELL VIABILITY; CONCENTRATION RESPONSE; DISEASE ASSOCIATION; DRUG STRUCTURE; ELECTRON TRANSPORT; ENZYME ACTIVATION; EXPERIMENTAL THERAPY; HUMAN; INNATE IMMUNITY; MITOCHONDRIAL ELECTRON TRANSPORT; MOLECULAR DYNAMICS; MOLECULARLY TARGETED THERAPY; NEOPLASM; NEOVASCULARIZATION (PATHOLOGY); NITROSYLATION; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PROCESSING; REVIEW; SIGNAL TRANSDUCTION; TUMOR ESCAPE; TUMOR GROWTH; TUMOR MICROENVIRONMENT; VASODILATATION; ANIMAL; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; METABOLISM; NEOPLASMS; PROCEDURES; TRENDS;

ANIMALS; ANTINEOPLASTIC AGENTS; CARBON MONOXIDE; GASOTRANSMITTERS; HUMANS; HYDROGEN SULFIDE; NEOPLASMS; NITRIC OXIDE; THERAPIES, INVESTIGATIONAL;

EID: 84959352390     PISSN: 14741776     EISSN: 14741784     Source Type: Journal    
DOI: 10.1038/nrd.2015.1     Document Type: Review

References (215)

1. Nathan, C. Nitric oxide as a secretory product of mammalian cells. FASEB J. 6, 3051-3064 (1992
2. Stuehr, D. J. Mammalian nitric oxide synthases. Biochim. Biophys. Acta 1411, 217-230 (1999
3. Liaudet, L., Soriano, F. G., & Szabo, C. Biology of nitric oxide signaling. Crit. Care Med. 28, N37-52 (2000
4. Ignarro, L. J. Nitric Oxide: Biology and Pathobiology 2nd edn (Academic Press, 2009
5. Southan, G. J., & Szabo, C. Selective pharmacological inhibition of distinct nitric oxide synthase isoforms. Biochem. Pharmacol. 51, 383-394 (1996
6. Joubert, J., & Malan, S. F. Novel nitric oxide synthase inhibitors: a patent review. Expert Opin. Ther. Pat. 21, 537-560 (2011
7. Szabo, C., Ischiropoulos, H., & Radi, R. Peroxynitrite: biochemistry, pathophysiology and development of therapeutics. Nat. Rev. Drug Discov. 6, 662-680 (2007
8. Pacher, P., Beckman, J. S., & Liaudet, L. Nitric oxide and peroxynitrite in health and disease. Physiol. Rev. 87, 315-424 (2007
9. Kröncke, K. D., Fehsel, K., & Kolb-Bachofen, V. Nitric oxide: cytotoxicity versus cytoprotection-how, why, when, and where?. Nitric Oxide 1, 107-120 (1997
10. Wink, D. A., et al. Mechanisms of the antioxidant effects of nitric oxide. Antioxid. Redox Signal. 3, 203-213 (2001
11. Thomas, D. D., et al. The chemical biology of nitric oxide: implications in cellular signaling. Free Radic. Biol. Med. 45, 18-31 (2008
12. Calabrese, V., et al. Nitric oxide in cell survival: a janus molecule. Antioxid. Redox Signal. 11, 2717-2739 (2009
13. Hibbs, J. B. Jr, Taintor, R. R., & Vavrin, Z. Macrophage cytotoxicity: role for l arginine deiminase and imino nitrogen oxidation to nitrite. Science 235, 473-476 (1987
14. Stuehr, D. J., & Nathan, C. F. Nitric oxide. A macrophage product responsible for cytostasis and respiratory inhibition in tumor target cells. J. Exp. Med. 169, 1543-1555 (1989
15. Cui, S., Reichner, J. S., Mateo, R. B., & Albina, J. E. Activated murine macrophages induce apoptosis in tumor cells through nitric oxide-dependent or-independent mechanisms. Cancer Res. 54, 2462-2467 (1994
16. MacMicking, J., Xie, Q. W., & Nathan, C. Nitric oxide and macrophage function. Annu. Rev. Immunol. 15, 323-350 (1997
17. Farias-Eisner, R., Sherman, M. P., Aeberhard, E., & Chaudhuri, G. Nitric oxide is an important mediator for tumoricidal activity in vivo. Proc. Natl Acad. Sci. USA 91, 9407-9411 (1994
18. Wang, B., et al. Intact nitric oxide synthase II gene is required for interferon-β-mediated suppression of growth and metastasis of pancreatic adenocarcinoma. Cancer Res. 61, 71-75 (2001
19. Wei, D., et al. Direct demonstration of negative regulation of tumor growth and metastasis by host-inducible nitric oxide synthase. Cancer Res. 63, 3855-3859 (2003
20. Menon, C., et al. Tumoricidal activity of high-dose tumor necrosis factor-α is mediated by macrophage-derived nitric oxide burst and permanent blood flow shutdown. Int. J. Cancer 123, 464-475 (2008
21. Kawakami, K., Kawakami, M., & Puri, R. K. Nitric oxide accelerates interleukin 13 cytotoxin-mediated regression in head and neck cancer animal model. Clin. Cancer Res. 10, 5264-5270 (2004
22. Wang, B., et al. A novel model system for studying the double-edged roles of nitric oxide production in pancreatic cancer growth and metastasis. Oncogene 22, 1771-1782 (2003
23. Shi, Q., et al. Influence of nitric oxide synthase II gene disruption on tumor growth and metastasis. Cancer Res. 60, 2579-2583 (2000
24. Konopka, T. E., et al. Nitric oxide synthase II gene disruption: implications for tumor growth and vascular endothelial growth factor production. Cancer Res. 61, 3182-3187 (2001
25. DiNapoli, M. R., Calderon, C. L., & Lopez, D. M. The altered tumoricidal capacity of macrophages isolated from tumor-bearing mice is related to reduce expression of the inducible nitric oxide synthase gene. J. Exp. Med. 183, 1323-1329 (1996
26. Weigert, A., & Brüne, B. Nitric oxide, apoptosis and macrophage polarization during tumor progression. Nitric Oxide 19, 95-102 (2008
27. Böhle, A., & Brandau, S. Immune mechanisms in bacillus Calmette-Guérin immunotherapy for superficial bladder cancer. J. Urol. 170, 964-969 (2003
28. Hosseini, A., et al. Enhanced formation of nitric oxide in bladder carcinoma in situ and in BCG treated bladder cancer. Nitric Oxide 15, 337-343 (2006
29. Shah, G., et al. iNOS expression and NO production contribute to the direct effects of BCG on urothelial carcinoma cell biology. Urol. Oncol. 32, 45.e1-45.e9 (2014
30. Mills, C. D., Shearer, J., Evans, R., & Caldwell, M. D. Macrophage arginine metabolism and the inhibition or stimulation of cancer. J. Immunol. 149, 2709-2714 (1992
31. Ma, Q., Hoper, M., Anderson, N., & Rowlands, B. J. Effect of supplemental l arginine in a chemical-induced model of colorectal cancer. World J. Surg. 20, 1087-1091 (1996
32. Yeh, C. L., Pai, M. H., Li, C. C., Tsai, Y. L., & Yeh, S. L. Effect of arginine on angiogenesis induced by human colon cancer: in vitro and in vivo studies. J. Nutr. Biochem. 21, 538-543 (2010
33. Brittenden, J., Heys, S. D., Ross, J., Park, K. G., & Eremin, O. Natural cytotoxicity in breast cancer patients receiving neoadjuvant chemotherapy: effects of l arginine supplementation. Eur. J. Surg. Oncol. 20, 467-472 (1994
34. Heys, S. D., et al. Dietary supplementation with l arginine: modulation of tumour-infiltrating lymphocytes in patients with colorectal cancer. Br. J. Surg. 84, 238-241 (1997
35. Buijs, N., et al. Perioperative arginine-supplemented nutrition in malnourished patients with head and neck cancer improves long-Term survival. Am. J. Clin. Nutr. 92, 1151-1156 (2010
36. Zhao, H., et al. Randomized clinical trial of arginine-supplemented enteral nutrition versus standard enteral nutrition in patients undergoing gastric cancer surgery. J. Cancer Res. Clin. Oncol. 139, 1465-1470 (2013
37. Ma, Q., Wang, Y., Gao, X., Ma, Z., & Song, Z. l arginine reduces cell proliferation and ornithine decarboxylase activity in patients with colorectal adenoma and adenocarcinoma. Clin. Cancer Res. 13, 7407-7412 (2007
38. Rahat, M. A., & Hemmerlein, B. Macrophage-Tumor cell interactions regulate the function of nitric oxide. Front. Physiol. 4, 144 (2013
39. Huerta, S., Chilka, S., & Bonavida, B. Nitric oxide donors: novel cancer therapeutics. Int. J. Oncol. 33, 909-927 (2008
40. Yasuda, H. Solid tumor physiology and hypoxia-induced chemo/radio-resistance: novel strategy for cancer therapy: nitric oxide donor as a therapeutic enhancer. Nitric Oxide 19, 205-216 (2008
41. Jeannin, J. F., et al. Nitric oxide-induced resistance or sensitization to death in tumor cells. Nitric Oxide 19, 158-163 (2008
42. De Ridder, M., Verellen, D., Verovski, V., & Storme, G. Hypoxic tumor cell radiosensitization through nitric oxide. Nitric Oxide 19, 164-169 (2008
43. Sonveaux, P., Jordan, B. F., Gallez, B., & Feron, O. Nitric oxide delivery to cancer: why and how?. Eur. J. Cancer 45, 1352-1369 (2009
44. Reynolds, M. M., et al. Applications for nitric oxide in halting proliferation of tumor cells. Biochem. Biophys. Res. Commun. 431, 647-651 (2013
45. Rigas, B., & Williams, J. L. NO donating NSAIDs and cancer: an overview with a note on whether NO is required for their action. Nitric Oxide 19, 199-204 (2008
46. Findlay, V. J., et al. Tumor cell responses to a novel glutathione S transferase-Activated nitric oxide-releasing prodrug. Mol. Pharmacol. 65, 1070-1079 (2004
47. McMurtry, V., et al. JS K, a nitric oxide-releasing prodrug, induces breast cancer cell death while sparing normal mammary epithelial cells. Int. J. Oncol. 38, 963-971 (2011
48. Duan, S., Cai, S., Yang, Q., & Forrest, M. L. Multi-Arm polymeric nanocarrier as a nitric oxide delivery platform for chemotherapy of head and neck squamous cell carcinoma. Biomaterials 33, 3243-3253 (2012
49. Carpenter, A. W., & Schoenfisch, M. H. Nitric oxide release: part II. Therapeutic applications. Chem. Soc. Rev. 41, 3742-3752 (2012
50. Rapozzi, V., et al. Nitric oxide-mediated activity in anti cancer photodynamic therapy. Nitric Oxide 30, 26-35 (2013
51. Heilman, B., & Mascharak, P. K. Light-Triggered nitric oxide delivery to malignant sites and infection. Philos. Trans. A Math. Phys. Eng. Sci. 371, 20120368 (2013
52. Sharma, K., & Chakrapani, H. Site-directed delivery of nitric oxide to cancers. Nitric Oxide 43, 8-16 (2014
53. Radomski, M. W., Jenkins, D. C., Holmes, L., & Moncada, S. Human colorectal adenocarcinoma cells: differential nitric oxide synthesis determines their ability to aggregate platelets. Cancer Res. 51, 6073-6078 (1991
54. Thomsen, L. L., & Miles, D. W. Role of nitric oxide in tumour progression: lessons from human tumours. Cancer Metastasis Rev. 17, 107-118 (1998
55. Jahani-Asl, A., & Bonni, A. iNOS: a potential therapeutic target for malignant glioma. Curr. Mol. Med. 13, 1241-1249 (2013
56. Heinecke, J. L., et al. Tumor microenvironment-based feed-forward regulation of NOS2 in breast cancer progression. Proc. Natl Acad. Sci. USA 111, 6323-6328 (2014
57. Granados-Principal, S., et al. Inhibition of iNOS as a novel effective targeted therapy against triple-negative breast cancer. Breast Cancer Res. 17, 25 (2015
58. Jenkins, D. C., et al. Roles of nitric oxide in tumor growth. Proc. Natl Acad. Sci. USA 92, 4392-4396 (1995
59. Kostourou, V., et al. The role of tumour-derived iNOS in tumour progression and angiogenesis. Br. J. Cancer 104, 83-90 (2011
60. Sikora, A. G., et al. Targeted inhibition of inducible nitric oxide synthase inhibits growth of human melanoma in vivo and synergizes with chemotherapy. Clin. Cancer Res. 16, 1834-1844 (2010
61. Juang, S. H., et al. Use of retroviral vectors encoding murine inducible nitric oxide synthase gene to suppress tumorigenicity and cancer metastasis of murine melanoma. Cancer Biother. Radiopharm. 12, 167-175 (1997
62. Papapetropoulos, A., García-Cardeña, G., Madri, J. A., & Sessa, W. C. Nitric oxide production contributes to the angiogenic properties of vascular endothelial growth factor in human endothelial cells. J. Clin. Invest. 100, 3131-3139 (1997
63. Sessa, W. C. Molecular control of blood flow and angiogenesis: role of nitric oxide. J. Thromb. Haemost. 7, s35-37 (2009
64. Ziche, M., & Morbidelli, L. Molecular regulation of tumour angiogenesis by nitric oxide. Eur. Cytokine Netw. 20, 164-170 (2009
65. Thomsen, L. L., et al. Selective inhibition of inducible nitric oxide synthase inhibits tumor growth in vivo: studies with 1400W, a novel inhibitor. Cancer Res. 57, 3300-3304 (1997)
66. Camp, E. R., et al. Roles of nitric oxide synthase inhibition and vascular endothelial growth factor receptor 2 inhibition on vascular morphology and function in an in vivo model of pancreatic cancer. Clin. Cancer Res. 12, 2628-2633 (2006
67. Lopez-Rivera, E., et al Inducible nitric oxide synthase drives mTOR pathway activation and proliferation of human melanoma by reversible nitrosylation of TSC2. Cancer Res. 74, 1067-1078 (2014
68. Wang, G. Y., Ji, B., Wang, X., & Gu, J. H. Anti-cancer effect of iNOS inhibitor and its correlation with angiogenesis in gastric cancer. World J. Gastroenterol. 11, 3830-3833 (2005
69. Tozer, G. M., et al. Nitric oxide synthase inhibition enhances the tumor vascular-damaging effects of combretastatin A-4 3 O phosphate at clinically relevant doses. Clin. Cancer Res. 15, 3781-3790 (2009
70. Cardnell, R. J., & Mikkelsen, R. B. Nitric oxide synthase inhibition enhances the antitumor effect of radiation in the treatment of squamous carcinoma xenografts. PLoS ONE 6, e20147 (2011
71. Wood, P. J., et al. Modification of energy metabolism and radiation response of a murine tumour by changes in nitric oxide availability. Biochem. Biophys. Res. Commun. 192, 505-510 (1993)
72. Wood, P. J., et al. Induction of hypoxia in experimental murine tumors by the nitric oxide synthase inhibitor, NG nitro l arginine. Cancer Res. 54, 6458-6463 (1994
73. Bolton, W. K., et al. Randomized trial of an inhibitor of formation of advanced glycation end products in diabetic nephropathy. Am. J. Nephrol. 24, 32-40 (2004
74. Brindicci, C., Ito, K., Torre, O., Barnes, P. J., & Kharitonov, S. A. Effects of aminoguanidine, an inhibitor of inducible nitric oxide synthase, on nitric oxide production and its metabolites in healthy control subjects, healthy smokers, and COPD patients. Chest 135, 353-367 (2009
75. López, A., et al. Multiple-center, randomized, placebo-controlled, double-blind study of the nitric oxide synthase inhibitor 546C88: effect on survival in patients with septic shock. Crit. Care Med. 32, 21-30 (2004
76. Alderton, W. K., et al. GW274150 and GW273629 are potent and highly selective inhibitors of inducible nitric oxide synthase in vitro and in vivo. Br. J. Pharmacol. 145, 301-312 (2005
77. Singh, D., et al. Selective inducible nitric oxide synthase inhibition has no effect on allergen challenge in asthma. Am. J. Respir. Crit. Care Med. 176, 988-993 (2007
78. Høivik, H. O., et al. Lack of efficacy of the selective iNOS inhibitor GW274150 in prophylaxis of migraine headache. Cephalalgia 30, 1458-1467 (2010
79. Seymour, M., et al. Ultrasonographic measures of synovitis in an early phase clinical trial: a double-blind, randomised, placebo and comparator controlled phase IIa trial of GW274150 (a selective inducible nitric oxide synthase inhibitor) in rheumatoid arthritis. Clin. Exp. Rheumatol. 30, 254-261 (2012
80. Hellio le Graverand, M. P., et al. A 2 year randomised, double-blind, placebo-controlled, multicentre study of oral selective iNOS inhibitor, cindunistat (SD 6010), in patients with symptomatic osteoarthritis of the knee. Ann. Rheum. Dis. 72, 187-195 (2013
81. Arai, Y. Method for treating cancer by combined use of drugs. PATENTSCOPE [online], https://patentscope. wipo.int/search/en/detail.jsf?docId=WO2014118946 (2014
82. Flitney, F. W., et al. Antitumor actions of ruthenium(III)-based nitric oxide scavengers and nitric oxide synthase inhibitors. Mol. Cancer Ther. 10, 1571-1580 (2011
83. Andrade, S. P., Hart, I. R., & Piper, P. J. Inhibitors of nitric oxide synthase selectively reduce flow in tumor-Associated neovasculature. Br. J. Pharmacol. 107, 1092-1095 (1992
84. Meyer, R. E., et al. Nitric oxide synthase inhibition irreversibly decreases perfusion in the R3230Ac rat mammary adenocarcinoma. Br. J. Cancer 71, 1169-1174 (1995
85. Gallo, O., et al. Role of nitric oxide in angiogenesis and tumor progression in head and neck cancer. J. Natl Cancer Inst. 90, 587-596 (1998
86. Jadeski, L. C., & Lala, P. K. Nitric oxide synthase inhibition by NG nitro l arginine methyl ester inhibits tumor-induced angiogenesis in mammary tumors. Am. J. Pathol. 155, 1381-1390 (1999
87. Kashiwagi, S., et al. NO mediates mural cell recruitment and vessel morphogenesis in murine melanomas and tissue-engineered blood vessels. J. Clin. Invest. 115, 1816-1827 (2005
88. Lampson, B. L., et al. Targeting eNOS in pancreatic cancer. Cancer Res. 72, 4472-4482 (2012
89. Kashiwagi, S., et al. Perivascular nitric oxide gradients normalize tumor vasculature. Nat. Med. 14, 255-257 (2008
90. Yang, Z., et al. Targeting nitric oxide signaling with nNOS inhibitors as a novel strategy for the therapy and prevention of human melanoma. Antioxid. Redox Signal. 19, 433-447 (2013
91. Ng, Q. S., et al. Effect of nitric-oxide synthesis on tumour blood volume and vascular activity: a phase I study. Lancet Oncol. 8, 111-118 (2007)
92. Maines, M. D. Heme oxygenase: function, multiplicity, regulatory mechanisms, and clinical applications. FASEB J. 2, 2557-2568 (1988
93. Otterbein, L. E., & Choi, A. M. Heme oxygenase: colors of defense against cellular stress. Am. J. Physiol. Lung Cell. Mol. Physiol. 279, L1029-L1037 (2000
94. Ryter, S. W., & Otterbein, L. E. Carbon monoxide in biology and medicine. Bioessays 26, 270-280 (2004
95. Wu, L., & Wang, R. Carbon monoxide: endogenous production, physiological functions, and pharmacological applications. Pharmacol. Rev. 57, 585-630 (2005
96. Motterlini, R., & Otterbein, L. E. The therapeutic potential of carbon monoxide. Nat. Rev. Drug Discov. 9, 728-743 (2010
97. Zuckerbraun, B. S., et al. Carbon monoxide signals via inhibition of cytochrome c oxidase and generation of mitochondrial reactive oxygen species. FASEB J. 21, 1099-1106 (2007)
98. Chin, B. Y., et al. Hypoxia-inducible factor 1α stabilization by carbon monoxide results in cytoprotective preconditioning. Proc. Natl Acad. Sci. USA 104, 5109-5114 (2007
99. Schacter, B. A., & Kurz, P. Alterations in hepatic and splenic microsomal electron transport system components, drug metabolism, heme oxygenase activity, and cytochrome P-450 turnover in Murphy-Sturm lymphosarcoma-bearing rats. Cancer Res. 42, 3557-3564 (1982
100. Was, H., Dulak, J., & Jozkowicz, A. Heme oxygenase 1 in tumor biology and therapy. Curr. Drug Targets 11, 1551-1570 (2010
101. Berberat, P. O., et al. Inhibition of heme oxygenase 1 increases responsiveness of pancreatic cancer cells to anticancer treatment. Clin. Cancer Res. 11, 3790-3798 (2005
102. Sass, G., et al. Inhibition of heme oxygenase 1 expression by small interfering RNA decreases orthotopic tumor growth in livers of mice. Int. J. Cancer 123, 1269-1277 (2008)
103. Alaoui-Jamali, M. A., et al. A novel experimental heme oxygenase 1 targeted therapy for hormone-refractory prostate cancer. Cancer Res. 69, 8017-8024 (2009
104. Li, Y., et al. PTEN deletion and heme oxygenase 1 overexpression cooperate in prostate cancer progression and are associated with adverse clinical outcome. J. Pathol. 224, 90-100 (2011
105. Sahoo, S. K., et al. Pegylated zinc protoporphyrin: a water-soluble heme oxygenase inhibitor with tumor-Targeting capacity. Bioconjug. Chem. 13, 1031-1038 (2002
106. Fang, J., et al. In vivo antitumor activity of pegylated zinc protoporphyrin: targeted inhibition of heme oxygenase in solid tumor. Cancer Res. 63, 3567-3574 (2003)
107. Hirai, K., Sasahira, T., Ohmori, H., Fujii, K., & Kuniyasu, H. Inhibition of heme oxygenase 1 by zinc protoporphyrin IX reduces tumor growth of LL/2 lung cancer in C57BL mice. Int. J. Cancer 120, 500-505 (2007
108. Nowis, D., et al. Zinc protoporphyrin IX, a heme oxygenase 1 inhibitor, demonstrates potent antitumor effects but is unable to potentiate antitumor effects of chemotherapeutics in mice. BMC Cancer 8, 197 (2008
109. Miyake, M., et al. Heme oxygenase 1 promotes angiogenesis in urothelial carcinoma of the urinary bladder. Oncol. Rep. 25, 653-660 (2011
110. Deng, R., et al. Inhibition of tumor growth and alteration of associated macrophage cell type by an HO 1 inhibitor in breast carcinoma-bearing mice. Oncol. Res. 20, 473-482 (2013
111. Gueron, G., et al. Critical role of endogenous heme oxygenase 1 as a tuner of the invasive potential of prostate cancer cells. Mol. Cancer Res. 7, 1745-1755 (2009
112. Zou, C., et al. Heme oxygenase 1: a molecular brake on hepatocellular carcinoma cell migration. Carcinogenesis 32, 1840-1848 (2011
113. Kappas, A., Drummond, G. S., Manola, T., Petmezaki, S., & Valaes, T. Sn protoporphyrin use in the management of hyperbilirubinemia in term newborns with direct Coombs-positive ABO incompatibility. Pediatrics 81, 485-497 (1988
114. Dover, S. B., Moore, M. R., Fitzsimmons, E. J., Graham, A., & McColl, K. E. Tin protoporphyrin prolongs the biochemical remission produced by heme arginate in acute hepatic porphyria. Gastroenterology 105, 500-506 (1993
115. Kappas, A., Drummond, G. S., Henschke, C., & Valaes, T. Direct comparison of Sn mesoporphyrin, an inhibitor of bilirubin production, and phototherapy in controlling hyperbilirubinemia in term and near-Term newborns. Pediatrics 95, 468-474 (1995)
116. Nakamura, H., Fang, J., Gahininath, B., Tsukigawa, K., & Maeda, H. Intracellular uptake and behavior of two types zinc protoporphyrin (ZnPP) micelles, SMA-ZnPP and PEG-ZnPP as anticancer agents; unique intracellular disintegration of SMA micelles. J. Control. Release 155, 367-375 (2011
117. Tsukigawa, K., Nakamura, H., Fang, J., Otagiri, M., & Maeda, H. Effect of different chemical bonds in pegylation of zinc protoporphyrin that affects drug release, intracellular uptake, and therapeutic effect in the tumor. Eur. J. Pharm. Biopharm. 89, 259-270 (2015
118. Pittalà, V., Salerno, L., Romeo, G., Modica, M. N., & Siracusa, M. A. A focus on heme oxygenase 1 (HO 1) inhibitors. Curr. Med. Chem. 20, 3711-3732 (2013
119. Bergstraesser, C., et al. Inhibition of VCAM 1 expression in endothelial cells by CORM 3: the role of the ubiquitin-proteasome system, 38, and mitochondrial respiration. Free Radic. Biol. Med. 52, 794-802 (2012
120. Schwer, C. I., et al. Carbon monoxide releasing molecule 2 CORM 2 represses global protein synthesis by inhibition of eukaryotic elongation factor eEF2. Int. J. Biochem. Cell Biol. 45, 201-212 (2013
121. Wegiel, B., et al. Carbon monoxide expedites metabolic exhaustion to inhibit tumor growth. Cancer Res. 73, 7009-7021 (2013)
122. Long, R., Salouage, I., Berdeaux, A., Motterlini, R., & Morin, D. CORM 3, a water soluble CO releasing molecule, uncouples mitochondrial respiration via interaction with the phosphate carrier. Biochim. Biophys. Acta 1837, 201-209 (2014
123. Vítek, L., et al. Antiproliferative effects of carbon monoxide on pancreatic cancer. Dig. Liver Dis. 46, 369-375 (2014)
124. Stamellou, E., et al. Different design of enzyme-Triggered CO releasing molecules (ET CORMs) reveals quantitative differences in biological activities in terms of toxicity and inflammation. Redox Biol. 2, 739-748 (2014)
125. Lee, W. Y., et al. The induction of heme oxygenase 1 suppresses heat shock protein 90 and the proliferation of human breast cancer cells through its byproduct carbon monoxide. Toxicol. Appl. Pharmacol. 274, 55-62 (2014
126. Foresti, R., Bani-Hani, M. G., & Motterlini, R. Use of carbon monoxide as a therapeutic agent: promises and challenges. Int. Care Med. 34, 649-658 (2008
127. Otterbein, L. E. Quoth the Raven: carbon monoxide and nothing more. Med. Gas Res. 3, 7 (2013
128. Plummer, A. L. The carbon monoxide diffusing capacity: clinical implications, coding, and documentation. Chest 134, 663-667 (2008
129. Vesely, A. E., et al. The effects of carbon monoxide on respiratory chemoreflexes in humans. Environ. Res. 94, 227-233 (2004
130. Mayr, F. B., et al. Effects of carbon monoxide inhalation during experimental endotoxemia in humans. Am. J. Respir. Crit. Care Med. 171, 354-360 (2005
131. Resch, H., Zawinka, C., Weigert, G., Schmetterer, L., & Garhöfer, G. Inhaled carbon monoxide increases retinal and choroidal blood flow in healthy humans. Invest. Ophthalmol. Vis. Sci. 46, 4275-4280 (2005
132. Bathoorn, E., et al. Anti-inflammatory effects of inhaled carbon monoxide in patients with COPD: a pilot study. Eur. Respir. J. 30, 1131-1137 (2007
133. Szabo, C. Hydrogen sulphide and its therapeutic potential. Nat. Rev. Drug Discov. 6, 917-935 (2007
134. Whiteman, M., Le Trionnaire, S., Chopra, M., Fox, B., & Whatmore, J. Emerging role of hydrogen sulfide in health and disease: critical appraisal of biomarkers and pharmacological tools. Clin. Sci. (Lond) 121, 459-488 (2011
135. Kimura, H. Hydrogen sulfide: its production, release and functions. Amino Acids 41, 113-121 (2011
136. Wallace, J. L., Ferraz, J. G., & Muscara, M. N. Hydrogen sulfide: an endogenous mediator of resolution of inflammation and injury. Antioxid. Redox Signal. 17, 58-67 (2012
137. Wang, R. Physiological implications of hydrogen sulfide: a whiff exploration that blossomed. Physiol. Rev. 92, 791-896 (2012
138. Shibuya, N., et al. A novel pathway for the production of hydrogen sulfide from d cysteine in mammalian cells. Nat. Commun. 4, 1366 (2013
139. Asimakopoulou, A., et al. Selectivity of commonly used pharmacological inhibitors for cystathionine β synthase (CBS) and cystathionine ? lyase (CSE). Br. J. Pharmacol. 169, 922-932 (2013
140. Papapetropoulos, A., et al. Hydrogen sulfide is an endogenous stimulator of angiogenesis. Proc. Natl Acad. Sci. USA 106, 21972-21977 (2009
141. Coletta, C., et al. Hydrogen sulfide and nitric oxide are mutually dependent in the regulation of angiogenesis and endothelium-dependent vasorelaxation. Proc. Natl Acad. Sci. USA 109, 9161-9166 (2012)
142. Szabo, C., et al. Regulation of mitochondrial bioenergetic function by hydrogen sulfide. Part I. Biochemical and physiological mechanisms. Br. J. Pharmacol. 171, 2099-2122 (2014
143. Szabo, C., et al. Tumor-derived hydrogen sulfide, produced by cystathionine-β synthase, stimulates bioenergetics, cell proliferation, and angiogenesis in colon cancer. Proc. Natl Acad. Sci. USA 110, 12474-12479 (2013)
144. Bhattacharyya, S., et al. Cystathionine beta-synthase (CBS) contributes to advanced ovarian cancer progression and drug resistance. PLoS ONE 8, e79167 (2013)
145. Guo, H., et al. Characterization of hydrogen sulfide and its synthases, cystathionine β synthase and cystathionine ? lyase, in human prostatic tissue and cells. Urology 79, 483.e1-483.e5 (2012
146. Sen, S., et al. Role of cystathionine β synthase in human breast cancer. Free Radic. Biol. Med. 86, 228-238 (2015
147. Chao, C., et al. Cystathionine-β synthetase inhibition in combination with standard-chemotherapy decreases colorectal cancer metastasis to the liver. Nitric Oxide 39, S21-S22 (2014
148. Takano, N., et al. Decreased expression of cystathionine β synthase promotes glioma tumorigenesis. Mol. Cancer Res. 12, 1398-1406 (2014
149. Hellmich, M. R., Coletta, C., Chao, C., & Szabo, C. The therapeutic potential of cystathionine β synthetase/hydrogen sulfide inhibition in cancer. Antioxid. Redox Signal. 22, 424-448 (2015
150. Panza, E., et al. Role of the cystathionine ? lyase/ hydrogen sulfide pathway in human melanoma progression. Pigment Cell Melanoma Res. 28, 61-72 (2015
151. De Vos, J., et al. Comparison of gene expression profiling between malignant and normal plasma cells with oligonucleotide arrays. Oncogene 21, 6848-6857 (2002
152. Hansel, D. E., et al. Identification of novel cellular targets in biliary tract cancers using global gene expression technology. Am. J. Pathol. 163, 217-229 (2003
153. Zhang, W., et al. Expression profiling of homocysteine junction enzymes in the NCI60 panel of human cancer cell lines. Cancer Res. 65, 1554-1560 (2005
154. Jurkowska, H., Placha, W., Nagahara, N., & Wróbel, M. The expression and activity of cystathionine-γ lyase and 3 mercaptopyruvate sulfurtransferase in human neoplastic cell lines. Amino Acids 41, 151-158 (2011
155. Szczesny, B., Brunyanszki, A., Hellmich, M. R., & Szabo, C. Hydrogen sulfide in lung adenocarcinoma: a tumor cell survival factor, an enhancer of mitochondrial DNA repair and a cellular bioenergetic stimulator. Nitric Oxide 47, S46 (2015
156. Fan, K., et al. Wnt/β catenin signaling induces the transcription of cystathionine-γ lyase, a stimulator of tumor in colon cancer. Cell Signal. 26, 2801-2808 (2014
157. Zatarain, J. R., et al. H2S inhibition of cystathionine-β synthase (CBS) using a novel prodrug decreases colorectal cancer xenograft growth with less toxicity than aminooxyacetic acid (AOAA). Gastroenterology 148, S950 (2015
158. Perry, T. L., et al. Failure of aminooxyacetic acid therapy in Huntington disease. Neurology 30, 772-775 (1980
159. Guth, P. S., et al. Evaluation of amino-oxyacetic acid as a palliative in tinnitus. Ann. Otol. Rhinol. Laryngol. 99, 74-79 (1990
160. Li, L., et al. Characterization of a novel, water-soluble hydrogen sulfide-releasing molecule (GYY4137): new insights into the biology of hydrogen sulfide. Circulation 117, 2351-2360 (2008
161. Han, Y., et al. Hydrogen sulfide inhibits abnormal proliferation of lymphocytes via AKT/GSK3β signal pathway in systemic lupus erythematosus patients. Cell. Physiol. Biochem. 31, 795-804 (2013
162. Lee, Z. W., et al. Utilizing hydrogen sulfide as a novel anti-cancer agent by targeting cancer glycolysis and pH imbalance. Br. J. Pharmacol. 171, 4322-4336 (2014
163. Lee, Z. W., et al. The slow-releasing hydrogen sulfide donor, GYY4137, exhibits novel anti-cancer effects in vitro and in vivo. PLoS ONE 6, e21077(2011)
164. Lu, S., Gao, Y., Huang, X., & Wang, X. GYY4137, a hydrogen sulfide (H2S) donor, shows potent anti-hepatocellular carcinoma activity through blocking the STAT3 pathway. Int. J. Oncol. 44, 1259-1267 (2014
165. Benavides, G. A., et al. Hydrogen sulfide mediates the vasoactivity of garlic. Proc. Natl Acad. Sci. USA 104, 17977-17982 (2007
166. Insko, M. A., Deckwerth, T. L., Hill, P., Toombs, C. F., & Szabo, C. Detection of exhaled hydrogen sulphide gas in rats exposed to intravenous sodium sulphide. Br. J. Pharmacol. 157, 944-951 (2009
167. Predmore, B. L., et al. The polysulfide diallyl trisulfide protects the ischemic myocardium by preservation of endogenous hydrogen sulfide and increasing nitric oxide bioavailability. Am. J. Physiol. Heart Circ. Physiol. 302, H2410-H2418 (2012
168. Yi, L., & Su, Q. Molecular mechanisms for the anti-cancer effects of diallyl disulfide. Food Chem. Toxicol. 57, 362-370 (2013
169. Singh, S. V., et al. Garlic constituent diallyl trisulfide prevents development of poorly differentiated prostate cancer and pulmonary metastasis multiplicity in TRAMP mice. Cancer Res. 68, 9503-9511 (2008
170. Wu, P. P., et al. Diallyl trisulfide (DATS) inhibits mouse colon tumor in mouse CT 26 cells allograft model in vivo. Phytomedicine 18, 672-676 (2011
171. Li, W., et al. Diallyl trisulfide induces apoptosis and inhibits proliferation of A549 cells in vitro and in vivo. Acta Biochim. Biophys. Sin. (Shanghai) 44, 577-583 (2012
172. Wallace, G. C., et al. Multi-Targeted DATS prevents tumor progression and promotes apoptosis in ectopic glioblastoma xenografts in SCID mice via HDAC inhibition. J. Neurooncol. 114, 43-50 (2013
173. Ma, K., et al. H2S donor, S propargyl-cysteine, increases CSE in SGC 7901 and cancer-induced mice: evidence for a novel anti-cancer effect of endogenous H2S?. PLoS ONE 6, e20525 (2011
174. Chattopadhyay, M., et al. Hydrogen sulfide-releasing aspirin suppresses NF ?B signaling in estrogen receptor negative breast cancer cells in vitro and in vivo. Biochem. Pharmacol. 83, 723-732 (2012
175. Kashfi, K., & Olson, K. R. Biology and therapeutic potential of hydrogen sulfide and hydrogen sulfide-releasing chimeras. Biochem. Pharmacol. 85, 689-703 (2013
176. Gemici, B., et al. H2S-releasing drugs: anti-inflammatory, cytoprotective and chemopreventative potential. Nitric Oxide 46, 25-31 (2015
177. Szabo, C. Gaseotransmitters: new frontiers for translational science. Sci. Transl. Med. 2, 59ps54 (2010
178. Chattopadhyay, M., Kodela, R., Olson, K. R., & Kashfi, K. NOSH-Aspirin (NBS 1120), a novel nitric oxide-And hydrogen sulfide-releasing hybrid is a potent inhibitor of colon cancer cell growth in vitro and in a xenograft mouse model. Biochem. Biophys. Res. Commun. 419, 523-528 (2012
179. Maksimovic-Ivanic, D., et al. Anticancer properties of the novel nitric oxide-donating compound (S, R)-3 phenyl 4 , 5 dihydro 5 isoxazole acetic acid-nitric oxide in vitro and in vivo. Mol. Cancer Ther. 7, 510-520 (2008
180. Mijatovic, S., et al. Induction of caspase-independent apoptotic-like cell death of mouse mammary tumor TA3Ha cells in vitro and reduction of their lethality in vivo by the novel chemotherapeutic agent GIT 27NO. Free Radic. Biol. Med. 48, 1090-1099 (2010
181. Donia, M., et al. In vitro and in vivo anticancer action of Saquinavir NO, a novel nitric oxide-derivative of the protease inhibitor saquinavir, on hormone resistant prostate cancer cells. Cell Cycle 10, 492-499 (2011
182. Donia, M., et al. Unique antineoplastic profile of Saquinavir NO, a novel NO derivative of the protease inhibitor Saquinavir, on the in vitro and in vivo tumor formation of A375 human melanoma cells. Oncol. Rep. 28, 682-688 (2012
183. Elsheikh, W., Blackler, R. W., Flannigan, K. L., & Wallace, J. L. Enhanced chemopreventive effects of a hydrogen sulfide-releasing anti-inflammatory drug (ATB 346) in experimental colorectal cancer. Nitric Oxide 41, 131-137 (2014
184. Moriyama, A., et al. Plasma nitrite/nitrate concentrations as a tumor marker for hepatocellular carcinoma. Clin. Chim. Acta 296, 181-191 (2000
185. Chan, H. P., Lewis, C., & Thomas, P. S. Exhaled breath analysis: novel approach for early detection of lung cancer. Lung Cancer 63, 164-168 (2009)
186. Yin, H., Fang, J., Liao, L., Maeda, H., & Su, Q. Upregulation of heme oxygenase 1 in colorectal cancer patients with increased circulation carbon monoxide levels, potentially affects chemotherapeutic sensitivity. BMC Cancer 14, 436 (2014)
187. Bonavida, B., & Baritaki, S. Dual role of NO donors in the reversal of tumor cell resistance and EMT: downregulation of the NF kB/Snail/YY1/RKIP circuitry. Nitric Oxide 24, 1-7 (2011
188. Bhowmick, R., & Girotti, A. W. Cytoprotective signaling associated with nitric oxide upregulation in tumor cells subjected to photodynamic therapy-like oxidative stress. Free Radic. Biol. Med. 57, 39-48 (2013
189. Furfaro, A. L., et al. HO 1 up regulation: a key point in high-risk neuroblastoma resistance to bortezomib. Biochim. Biophys. Acta 1842, 613-622 (2014
190. Sanokawa-Akakura, R., Ostrakhovitch, E. A., Akakura, S., Goodwin, S., & Tabibzadeh, S. A H2S-Nampt dependent energetic circuit is critical to survival and cytoprotection from damage in cancer cells. PLoS ONE 9, e108537 (2014
191. Ostrakhovitch, E. A., Akakura, S., Sanokawa-Akakura, R., Goodwin, S., & Tabibzadeh, S. Dedifferentiation of cancer cells following recovery from a potentially lethal damage is mediated by H2S-Nampt. Exp. Cell Res. 330, 135-150 (2015
192. Eyler, C E., et al. Glioma stem cell proliferation and tumor growth are promoted by nitric oxide synthase 2. Cell 146, 53-66 (2011
193. Herrmann, H., et al. The Hsp32 inhibitors SMA-ZnPP and PEG-ZnPP exert major growth-inhibitory effects on D34+/CD38+ and CD34+/CD38-AML progenitor cells. Curr. Cancer Drug Targets 12, 51-63 (2012
194. Kim, R. K., et al. Fractionated radiation-induced nitric oxide promotes expansion of glioma stem-like cells. Cancer Sci. 104, 1172-1177 (2013
195. Rao, C. V. Nitric oxide signaling in colon cancer chemoprevention. Mutat. Res. 555, 107-119 (2004
196. Bonavida, B., Khineche, S., Huerta-Yepez, S., & Garbán, H. Therapeutic potential of nitric oxide in cancer. Drug Resist. Updat. 9, 157-173 (2006
197. Burke, A. J., Sullivan, F. J., Giles, F. J., & Glynn, S. A. The yin and yang of nitric oxide in cancer progression. Carcinogenesis 34, 503-512 (2013
198. Grochot-Przeczek, A., Dulak, J., & Jozkowicz, A. Haem oxygenase 1: non-canonical roles in physiology and pathology. Clin. Sci. (Lond). 122, 93-103 (2012
199. Carbonero, F., Benefiel, A. C., & Gaskins, H. R. Contributions of the microbial hydrogen economy to colonic homeostasis. Nat. Rev. Gastroenterol. Hepatol. 9, 504-518 (2012
200. Kilbourn, R. G., et al. Inhibition of interleukin 1 α-induced nitric oxide synthase in vascular smooth muscle and full reversal of interleukin 1 α-induced hypotension by Nγ-Amino l arginine. J. Natl Cancer Inst. 84, 1008-1016 (1992
201. Kilbourn, R. G., Szabo, C., & Traber, D. L. Beneficial versus detrimental effects of nitric oxide synthase inhibitors in circulatory shock: lessons learned from experimental and clinical studies. Shock 7, 235-246 (1997
202. Kondapaneni, M., McGregor, J. R., Salvemini, D., Laubach, V. E., & Samlowski, W. E. Inducible nitric oxide synthase (iNOS) is not required for IL 2 induced hypotension and vascular leak syndrome in mice. J. Immunother. 31, 325-333 (2008
203. Samlowski, W. E., et al. Endothelial nitric oxide synthase is a key mediator of interleukin 2 induced hypotension and vascular leak syndrome. J. Immunother. 34, 419-427 (2011
204. Maybauer, D. M., et al. Lung-protective effects of the metalloporphyrinic peroxynitrite decomposition catalyst WW 85 in interleukin 2 induced toxicity. Biochem. Biophys. Res. Commun. 377, 786-791 (2008
205. Kilbourn, R. G., Fonseca, G. A., Trissel, L. A., & Griffith, O. W. Strategies to reduce side effects of interleukin 2: evaluation of the antihypotensive agent NG monomethyl-l arginine. Cancer J. Sci. Am. 6, S21-S30 (2000)
206. Ashburn, T. T., & Thor, K. B. Drug repositioning: identifying and developing new uses for existing drugs. Nat. Rev. Drug Discov. 3, 673-683 (2004
207. Blatt, J., & Corey, S. J. Drug repurposing in pediatrics and pediatric hematology oncology. Drug Discov. Today 18, 4-10 (2013
208. Stenvang, J., et al. Biomarker-guided repurposing of chemotherapeutic drugs for cancer therapy: a novel strategy in drug development. Front. Oncol. 3, 313 (2013
209. Quinn, B. J., et al. Repositioning metformin for cancer prevention and treatment. Trends Endocrinol. Metab. 24, 469-480 (2013
210. Jordan, B. F., et al. Nitric oxide as a radiosensitizer: evidence for an intrinsic role in addition to its effect on oxygen delivery and consumption. Int. J. Cancer 109, 768-773 (2004
211. Oronsky, B. T., Knox, S. J., & Scicinski, J. J. Is nitric oxide (NO) the last word in radiosensitization?. A review. Transl. Oncol. 5, 66-71 (2012
212. Arrieta, O., et al. Phase II study. Concurrent chemotherapy and radiotherapy with nitroglycerin in locally advanced non-small cell lung cancer. Radiother. Oncol. 111, 311-315 (2014
213. Reid, T., et al. Two case reports of resensitization to previous chemotherapy with the novel hypoxia-Activated hypomethylating anticancer agent RRx 001 in metastatic colorectal cancer patients. Case Rep. Oncol. 7, 79-85 (2014
214. Jiang, H., et al. Activated macrophages as a novel determinant of tumor cell radioresponse: the role of nitric oxide-mediated inhibition of cellular respiration and oxygen sparing. Int. J. Radiat. Oncol. Biol. Phys. 76, 1520-1527 (2010
215. de Bono, J. S., et al. Phase I study of ONO 4007, a synthetic analogue of the lipid A moiety of bacterial lipopolysaccharide. Clin. Cancer Res. 6, 397-405 (2000